Availability of Vaccines Could be Year to Year and Half - HHS
Tweet
Share
E-mail
Get Alerts GILD Hot Sheet
Price: $151.00 -0.15%
Overall Analyst Rating:
SELL (= Flat)
Dividend Yield: 2.3%
Revenue Growth %: -0.3%
Overall Analyst Rating:
SELL (= Flat)
Dividend Yield: 2.3%
Revenue Growth %: -0.3%
Join SI Premium – FREE
(Updated - February 25, 2020 3:18 PM EST)
(Updated - February 25, 2020 3:17 PM EST)
Community Spread of Coronavirus in Other Countries Outside China Very Concerning - HHS
- Intimidate Risk in U.S. is Low, Must Continue to Prepare
- Vaccine Development on Time, in Human Trial in Month and Half
- Availability of Vaccines Could be Year to Year and Half
- Results of Trials with Gilead's (NASDAQ: GILD) Remdesivir Antiviral Expected in Reasonable Time
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- JPMorgan hires healthcare banker David Blais from Guggenheim, sources say
- Jefferies says retail fund inflows reach $25.3bn in latest week
- Dell’s earning report was bullish for Intel CPU demand, analyst says
Create E-mail Alert Related Categories
General News, PoliticsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
